Worst performer was last week's Share of the Week TAP:Taptica, which gave up all of last week's gains and some as it dropped 11%. I can't help thinking this is massively under-valued now. I may have to re-think what to do with my £2,000 pension transfer...
IKA:Ilika continues to be rubbish and miles off ever making a profit, dropping another 7% this week to go 75% down on my purchase price. I'm glad I only dipped a £500 toe in this one as it's doomed unless a miracle occurs.
TLOU:Tlou Energy had yet another bad week and dropped 6%. This one's very disappointing, but I still think it will come good. It's very high risk though, and I think the sort of company I will avoid in future. My biggest fear is they will sell out the reserves while the price is this low, as I'm down 55% and I put in £2,700 so stand to lose a lot if they don't hang around until profitable.
Only three big losers this week, but 5 big gainers. WRES:W Resources recovered from last week's losses and climbed 5% probably as a result of a nice video showing the new crusher in operation. It is quite impressive, and they will be producing soon, but with massive share dilution and what appears to be a crippling debt facility, I won't be hanging around for the long term. I only invested £430 and that was mostly dividends and profits from another sale I was looking to do something with.
SAE:Simec Atlantis Energy is another of my small investments, and good job as it's dropped 65% since I bought them. I think they could be successful in the long term, but have one small source of revenue and potentially massive costs to get anything bigger coming in. They climbed 6% this week but there's a long way to go yet.
AMYT:Amryt Pharma have been surprisingly low for a while now, given they are revenue-generating and in Phase III trials. I guess there's a worry the trials will fail and that's spooked people out, and my recent experience with junior pharmas suggests that might be a prudent approach. However, these have several strings to their bow, and don't forget Harry Stratford as Chair. I made £400 profit when I sold my initial holding, and these are only 9% down and losing £139 so I'm up overall with this company and will be staying invested for the long term.
MAIS:Maistro climbed 16% on paper this week, but that's not entirely accurate as I took part in an open offer. I applied for 4,000 at 1p each but my allocation was only meant to be 40 and I managed to get 1,339 costing just £13.39 with no commission. My initial holding was from when this was BLUR:Blur Group and was 400 bought at 24.225p. They were down by 107% prior to the open offer. Now my weighted average has dropped to 6.34p and they are only down by 91% so all looking rosy! The chances of them ever making a profit are very slim, and they may very well go bust, but for a minuscule injection I've improved my chances of getting out without a loss. If the whole thing goes bust I'll only have lost £122 as I bought these before I understood the importance of commission and sensible minimum investment amounts - and not to back a complete donkey just because the share price is at a 12-month low.
I'm very happy to say that OPTI:Optibiotix wins Share of the Week with a 17% climb. That was 11p and added up to £8,800. So without OPTI:Optibiotix I would have been down £200 this week. The momentum is really building now, and although the promised "Christmas surprise" was a bit lame, there's clearly a ton of stuff about to happen in the New Year and revenue flow must be really building. After collapsing to a loss a few weeks ago, my paper profits are back up to £22,430. Traders must have made an absolute fortune out of this share as it's been up and down like a yo-yo. I just keep buying more on the dips, but I'm hoping there won't be any more dips. Now I have 79,877 shares I think that's probably enough. When they get to £5 a share (which they will) I'll have made well over £300,000 profit. They could quite easily get to £10 a share once Sweetbiotix takes off, and that will give me $750K. The plan is to spin out each division but retain 75% of the shares and act as a holding company - the model Berkshire Hathaway uses. Allow the subsidiaries to take all the risk and do all the work, then just hoover up the profits. Slimbiome Medical starts selling in January and that could be surprisingly lucrative, and was a complete bonus following the CE Mark award and medical device approval a few weeks ago. It's all getting very exciting!
Bouncing along the red line
The ISA and share portfolios look like this
| Weekly Change | |||
| Cash | £46.66 | +£16.61 | |
| Portfolio cost | £56,971.94 | +£13.39 | |
| Portfolio sell value (bid price - commission) | £60,746.44 | (6.6%) | +£5,495.36 |
| Potential profits | £14,402.69 | +£5,565.56 | |
| Yr 4 Dividends | £60.50 | +£0 | |
| Yr 4 Profit from sales | £814.53 | +£0 | |
| Yr 4 Average monthly cash profit | £185.53 | (3.9%) | -£9.76 |
| Total Dividends | £1,298.83 | +£0 | |
| Total Profit from sales | £19,511.65 | +£0 | |
| Average monthly cash profit | £508.31 | (10.7%) | -£2.90 |
| (Sold stocks profit + Dividends - Fees / Months) |
Cash went up a bit as I added £30 for the open offer but didn't get to spend it all. Cost went up by the £13.39 for the open offer. All the increase was down to increasing OPTI:Optibiotix profits, and the rest of the portfolio slipped a bit but not a lot.
Sad to say that OPTI:Optibiotix is the only share in profit. The other 16 are all making a loss. JLP:Jubilee Metals and KIBO:Kibo Energy are both down by over £2,000 and TLOU:Tlou Energy by £1,487. All of them are mining/energy companies in Africa!
Looks like I have 7 months until my average monthly performance drops below 10%, which is perfect as I either don't want to sell, or for the majority I won't sell at a loss.
Back in the black, but the heady days of almost £80,000 are looking quite a long way in the past
The SIPP looks like this after week 160
| Weekly Change | |||
| Cash | £138.64 | +£0 | |
| Portfolio cost | £35,825.45 | +£0 | |
| Portfolio sell value (bid price - commission) | £40,882.50 | (14.1%) | +£3,200.45 |
| Potential profits | £9,125.87 | +£3,210.63 | |
| Yr 4 Dividends | £0 | +£0 | |
| Yr 4 Interest | £0 | +£0 | |
| Yr 4 Profit from sales | £0 | +£0 | |
| Yr 4 Average monthly cash profit | -£16.34 | (-0.5%) | +£5.45 |
| Total Dividends | £1,342.25 | +£0 | |
| Total Interest | £0.03 | +£0 | |
| Total Profit from sales | £10,544.92 | +£0 | |
| Average monthly cash profit | £314.52 | (10.5%) | -£1.98 |
| (Sold stocks profit + Dividends - Fees / Months) |
Nearly all the rise was OPTI:Optibiotix, but both CEY:Centamin and PAF:Pan African Resources contributed small rises in profits too. Unlike the other portfolio, four shares are in profit and six at a loss in the SIPP. Unfortunately, when I invest my £2,000 transfer next week it's going to increase the cost of the portfolio and that's likely to bring my average monthly profits down below 10% as the target is based percentage return against the current cost of the portfolio.
Although the value is at an all time high, it's on the back of an £8,000 injection a few weeks ago, so still a way to go to match the amazing position 3 months ago.
The trading account looks like this after week 126
| Weekly Change | |||
| Cash | £18.80 | +£0 | |
| Portfolio cost | £2,321.29 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,339.38 | (-42.3%) | -£60.19 |
| Potential profits | £0 | +£0 | |
| Year 3 Dividends | £17.33 | +£0 | |
| Year 3 Profit | £177.06 | +£0 | |
| Yr 3 Average monthly cash profit | £38.29 | (19.8%) | -£1.82 |
| Dividends | £18.48 | +£0 | |
| Profit from sales | -£64.29 | +£0 | |
| Average monthly cash profit | -£1.58 | (-0.8%) | +£0.01 |
| (Sold stocks profit + Dividends - Fees / Months) |
Yet another rubbish week. This account really is cursed. Everything dropped this week. The only glimmer of light is that year 3 is actually almost 20% up on projected profits after 5 months. All it takes is one of these to turn around and I can get the entire account into long term realised profit, despite paper profit being so bad. I'm still confident everything in this portfolio will come good, but in the long term, and that's not what a trading account is meant to be about. This has been a very tough and long lesson, and certainly hasn't been a profitable one - yet...
This is just too depressing to even look at! Pretty colours though...
Not quite the end of the year yet, so I guess that round-up can wait until next week. I'll have spent my £2,000 although I'm no longer sure what I'll spend it on. I desperately want to trade SBTX:SkinBiotherapeutics for a bit, as I've not been able to do it with OPTI:Optibiotix for fear of missing out on dividends. Given I have my longer term holding in SBTX:SkinBioTherapeutics (because it's at a loss), I want to use half my pension transfer to buy some while they're cheap, with the intention of selling around 20p then waiting for the next dip before buying more. I intended to do that with my other account but bought way too soon as the dip continued.
The other £1,000 was destined for CAML:Central Asia Metals, but I have a lot of these now and it would increase my average price, so I'm looking at both IQE:IQE and TAP:Taptica which are good companies that have been hammered recently and should bounce back. The question is, which is most likely to bounce back quickest? My decision will be revealed next week...
No comments:
Post a Comment